Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 301

Drug Profile

CV 301

Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; Falimarev-inalimarev; Inalimarev-falimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 06 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Bristol-Myers Squibb; National Cancer Institute (USA)
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 15 Aug 2019 Bavarian Nordic plans clinical trials in 2019
  • 06 May 2019 CV 301 is available for licensing as of 06 May 2019. http://www.bavarian-nordic.com/
  • 19 Sep 2018 Phase-II clinical trials in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (SC) (NCT03628716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top